Pharmacology & ToxicologyAntimicrobial Agents and ChemotherapyPeer-reviewed
Author
R. Tasneen
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2019-2022 · peak 3/yrCo-Author Collaboration Network
10 top collaborators · 29 mutual co-author linksFocal author (center)Selected co-authorORCID co-authorUnlinked name
Curved chords = mutual co-authorship9 papers
Recent·Most cited
- ImmunologybioRxiv
An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis
S. Karanika, J. Gordy, P. Neupane…·P. Karakousis
This paper develops a DNA vaccine targeting dendritic cells that enhances isoniazid efficacy against tuberculosis by inducing strong immune responses and reducing Mtb burden.
DOI 10.3389/fimmu.2022.972266 - MicrobiologybioRxiv
Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models
E. Nuermberger, R. Tasneen, A. Garcia…·K. E. Dooley
This paper tests novel tuberculosis treatment regimens in mice, finding that BZM-based regimens show improved sterilizing activity compared to standard care.
DOI 10.1128/aac.02398-21 - MicrobiologybioRxiv
Combination of Mycobacterium tuberculosis RS ratio and CFU improves the ability of murine efficacy experiments to distinguish between drug treatments
DOI 10.1128/aac.02310-21 - PathologybioRxiv
Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis
R. Tasneen, D. S. Mortensen, P. J. Converse…·N. Hawryluk
This study compares the efficacy of mTOR inhibitors in tuberculosis treatment, finding that CC214-2 reduces relapses more than rapamycin in mouse models.
DOI 10.1128/aac.00253-21 - Pharmacology & ToxicologybioRxiv
Preserved efficacy and reduced toxicity with intermittent linezolid dosing in combination with bedaquiline and pretomanid in a murine TB model
DOI 10.1128/aac.01178-20 - MicrobiologybioRxiv
Telacebec for ultra-short treatment of Buruli ulcer in a mouse model
D. Almeida, P. J. Converse, T. F. Omansen…·E. Nuermberger
This study evaluates Telacebec's efficacy in shortening Buruli ulcer treatment in mice, showing it can cure infections in as little as 1 week with no relapse.
DOI 10.1128/aac.00259-20 - MicrobiologybioRxiv
Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis
V. Saini, N. C. Ammerman, Y. S. Chang…·J. H. Grosset
This study tests a new TB treatment regimen combining high-dose rifapentine and clofazimine in mouse models, finding it more effective than either drug alone in shortening treatment duration.
DOI 10.1128/aac.00388-19 - Pharmacology & ToxicologybioRxiv
Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis
J. Xu, S.-Y. Li, D. Almeida…·E. Nuermberger
This study shows pretomanid improves the efficacy of TB treatment regimens in mice by reducing relapse and bedaquiline resistance.
DOI 10.1128/aac.00021-19